🔥 Gout-Kidney Stone Connection Simulator

Chronic Hyperuricemia and Acidic Baseline Urine

Elevated serum urate quietly sets the stage for stone disease.

• 6.8 mg/dL: Serum urate threshold (solubility limit at 37°C)
• ~25%: Gout patients w/ stones (lifetime prevalence)
• ~5.0–5.5: Typical gout urine pH (persistently acidic)
• 5.35: Uric acid pKa (controls ionization)

Why urate builds up

Overproduction or underexcretion raises serum urate over years.

Acidic urine phenotype

Gout patients excrete unusually acidic urine independent of diet.

Linking gout to stones

Shared metabolic defect drives both joint and kidney disease.

Low urine pH, not urate load alone, drives stone risk.

Urate Supersaturation in the Collecting Ducts

Concentrated, acidic urine pushes uric acid past its solubility limit.

• ~15 mg/dL: Uric acid solubility, pH 5 (poorly soluble)
• ~200 mg/dL: Solubility, pH 7 (far more soluble)
• ~700 mg: Daily urate excretion (chronic hyperuricemia)
• ~10–50×: Urine concentrating factor (plasma to urine)

pH-dependent solubility

Ionized urate is far more soluble than undissociated uric acid.

Concentration in the duct

Water reabsorption concentrates urate as urine travels distally.

Supersaturation index

When concentration exceeds solubility, crystallization becomes likely.

A saturation index above 1.0 marks the crystallization threshold.

Crystal Nucleation and Stone Growth

Microscopic crystals nucleate, aggregate, and anchor into a stone.

• SI > 1.0: Nucleation onset (saturation index)
• 1–2 mm/mo: Typical stone growth (untreated, high SI)
• ~10%: Uric acid stone share (of all kidney stones)
• Yes: Radiolucency (invisible on plain X-ray)

Nucleation kinetics

Ion clusters exceed a critical size and become stable crystals.

Aggregation into a stone

Crystals adhere to each other and to duct epithelium over time.

Clinical consequence

Growing stones obstruct flow and trigger renal colic.

Without intervention, stone mass accumulates continuously.

Hydration and Urine Alkalinization with Citrate

Fluids dilute urate while citrate raises pH toward solubility.

• ≥2.5–3 L/day: Target fluid intake (urine volume >2 L)
• 6.5–7.0: Target urine pH (potassium citrate therapy)
• 20–40 mEq/day: Citrate dose (typical) (divided doses)
• ~50%: Risk reduction, adequate fluid (stone recurrence)

Dilution effect

Higher urine volume lowers urate concentration directly.

Alkalinization mechanism

Citrate metabolism raises urine pH, ionizing more urate.

Combined strategy

Fluid and citrate together outperform either alone.

Raising pH from 5.0 to 6.5 can multiply solubility tenfold.

Stone Dissolution and Prevention of Recurrence

Sustained alkaline, dilute urine dissolves stones and blocks new ones.

• ~70–90%: Dissolution success rate (pure uric acid stones)
• Weeks–months: Time to dissolve (with sustained therapy)
• ~50%: Recurrence w/o therapy (within 5 years)
• <15%: Recurrence w/ therapy (sustained adherence)

Chemical dissolution

Alkaline urine slowly redissolves existing uric acid stones.

Preventing new nucleation

Maintained low saturation index stops new crystals forming.

Long-term management

Lifelong hydration and pH monitoring sustain remission.

Prevention is cheaper and safer than repeated stone removal.